Supraventricular tachycardia drug of choice
Supraventricular tachycardia drug of choice Supraventricular tachycardia (SVT) is a common arrhythmia characterized by an abnormally fast heart rate originating above the ventricles. Patients often experience palpitations, dizziness, shortness of breath, or chest discomfort during episodes. Prompt and effective management is crucial to alleviate symptoms, prevent complications, and restore normal heart rhythm. Among the various treatment strategies, pharmacotherapy plays a pivotal role, especially in acute episodes and long-term control.
Supraventricular tachycardia drug of choice The primary goal in managing SVT with medication is to terminate the arrhythmia promptly and prevent its recurrence. The choice of drug depends on the patient’s hemodynamic stability, underlying heart conditions, and the frequency or severity of episodes. In stable patients presenting with SVT, vagal maneuvers are often the first line of intervention. Techniques such as carotid sinus massage or the Valsalva maneuver can increase parasympathetic tone, which may successfully terminate the arrhythmia in some cases.
When vagal maneuvers fail or are contraindicated, pharmacologic therapy becomes necessary. The drug of choice for acute termination of SVT in most cases is adenosine. Adenosine is an ultra-rapid-acting nucleoside that temporarily blocks atrioventricular (AV) nodal conduction. Its rapid onset (within seconds) and short half-life (approximately 10 seconds) make it highly effective for transiently interrupting reentrant pathways responsible for SVT. Typical initial doses start at 6 mg intravenously, followed by 12 mg if the first dose is ineffective. Repeated doses may be administered if needed, with caution to monitor patient response.
Adenosine is favored due to its high efficacy, safety profile, and minimal side effects when administered correctly. Common adverse effects include flushing, chest discomfort, or brief asystole, but these are usually transient. It is contraindicated in patients with certain conditions such as second- or third-degree AV block, sick sinus syndrome, or severe asthma due to potential bronchospasm. Supraventricular tachycardia drug of choice
For patients with recurrent episodes or those who do not tolerate adenosine, other antiarrhythmic drugs are considered. Calcium channel blockers, notably verapamil and diltiazem, are effective in controlling AV nodal conduction and can be used both acutely and for long-term suppression. These agents decrease conduction velocity through the AV node, thereby preventing reentry circuits that cause SVT. However, they should be used cautiously in patients with left ventricular dysfunction or hypotension.
Supraventricular tachycardia drug of choice Beta-blockers, such as metoprolol or propranolol, are also valuable in preventing recurrent SVT episodes. They reduce sympathetic stimulation, decrease heart rate, and suppress conduction through the AV node. They are particularly useful in patients with underlying hypertension or ischemic heart disease.
Supraventricular tachycardia drug of choice In more resistant cases or in patients with contraindications to pharmacotherapy, catheter ablation of the accessory pathways or reentrant circuits offers a definitive cure. This procedure has high success rates and is recommended for patients with frequent or debilitating episodes.
In summary, the drug of choice for acute termination of SVT is adenosine, owing to its rapid action and high efficacy. Calcium channel blockers and beta-blockers serve as effective options for ongoing management and prevention. Tailoring therapy to individual patient needs and comorbidities is essential for optimal outcomes. Supraventricular tachycardia drug of choice